Pherecydes Pharma
A clinical-stage biotech company developing phage therapy for resistant infections.
ALPHE | PA
Overview
Corporate Details
- ISIN(s):
- FR0011651694
- LEI:
- 894500LYT3UUN58X3I68
- Country:
- France
- Address:
- 22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
Description
Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-27 17:45 |
Rapports financiers et d'audit annuels / Rapport financier annuel
|
French | 2.2 MB | ||
| 2023-04-17 07:00 |
Inside Information / Other news releases
|
English | 200.3 KB | ||
| 2023-04-17 07:00 |
Informations privilégiées / Autres communiqués
|
French | 227.8 KB | ||
| 2023-04-06 17:45 |
Inside Information / Other news releases
|
English | 189.5 KB | ||
| 2023-04-06 17:45 |
Informations privilégiées / Autres communiqués
|
French | 197.2 KB | ||
| 2023-03-30 18:12 |
Informations privilégiées / Autres communiqués
|
French | 326.8 KB | ||
| 2023-03-30 18:12 |
Inside Information / Other news releases
|
English | 322.3 KB | ||
| 2023-03-27 07:00 |
Inside Information / Other news releases
|
English | 237.8 KB | ||
| 2023-03-27 07:00 |
Informations privilégiées / Autres communiqués
|
French | 236.8 KB | ||
| 2023-02-17 22:37 |
Informations privilégiées / Autres communiqués
|
French | 277.7 KB | ||
| 2023-02-17 22:37 |
Inside Information / Other news releases
|
English | 260.4 KB | ||
| 2023-02-15 23:54 |
Inside Information / Other news releases
|
English | 348.6 KB | ||
| 2023-02-15 23:54 |
Informations privilégiées / Autres communiqués
|
French | 354.8 KB | ||
| 2023-02-08 18:54 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 179.2 KB | ||
| 2023-01-25 17:45 |
Inside Information / Other news releases
|
English | 225.5 KB |
Automate Your Workflow. Get a real-time feed of all Pherecydes Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pherecydes Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pherecydes Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
